The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.
A network meta-analysis highlights the impact of individual risk profiles on the absolute benefits offered by GLP-1 receptor agonists and SGLT2 inhibitors for people with type 2 diabetes.
Adding the SGLT2 inhibitor empagliflozin to standard treatment significantly improves left ventricular remodeling among patients with heart failure and reduced ejection fraction but without diabetes, shows a randomized controlled trial.